Publications by authors named "David Plowchalk"

Claim this Profile
P
Population PK/PD modeling of low-density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti-PCSK9 monoclonal antibody.
Ellen Q Wang, Nitin Kaila, David Plowchalk, Leonid Gibiansky, Carla Yunis

CPT Pharmacometrics Syst Pharmacol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co-mixture with recombinant human hyaluronidase: A phase 1 randomized trial.
Almasa Bass, Anna Plotka, Khurshid Mridha, Catherine Sattler, Albert M Kim, David R Plowchalk

Health Sci Rep· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.
Christie M Ballantyne, Joel Neutel, Anne Cropp, William Duggan, Ellen Q Wang, David Plowchalk

Am J Cardiol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel, selective vitamin D analog suppresses parathyroid hormone in uremic animals and postmenopausal women.
Julia B Zella, Lori A Plum, David R Plowchalk, Michael Potochoiba, Margaret Clagett-Dame

Am J Nephrol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development.
Ernesto Callegari, Amit S Kalgutkar, Louis Leung, R Scott Obach, David R Plowchalk

Drug Metab Dispos· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2.
David R Plowchalk, Karen Rowland Yeo

Eur J Clin Pharmacol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling.
Hannah M Jones, Iain B Gardner, Wendy T Collard, Phil J Stanley, Penny Oxley, David Plowchalk

Clin Pharmacokinet· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.
Odette A Fahmi, Susan Hurst, David Plowchalk, Jack Cook, Feng Guo

Drug Metab Dispos· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.
Kuresh A Youdim, Aref Zayed, Maurice Dickins, Alex Phipps, Michelle Griffiths, David R Plowchalk

Br J Clin Pharmacol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbits.
David M Flynn, Andrew H Smith, Judith L Treadway, Carolyn B Levy, Walter C Soeller, David R Plowchalk

Cardiovasc Drugs Ther· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a physiologically based pharmacokinetic model for estradiol in rats and humans: a biologically motivated quantitative framework for evaluating responses to estradiol and other endocrine-active compounds.
David R Plowchalk, Justin Teeguarden

Toxicol Sci· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis